Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


One In Five New EU Filings Are For Biosimilars

Executive Summary

The European Medicines Agency received 17 filings for biosimilar medicines last year, accounting for 18% of all centralized marketing authorization applications. As of April 2018, the EMA had received a total of 77 biosimilar MAAs. Scientific advice is also proving popular with biosimilar developers, and the agency has been upping its communications to stakeholders such as healthcare professionals and the public.

You may also be interested in...

More Biosimilars Of Herceptin And Remicade Get EMA Yes

The EMA’s CHMP has adopted positive opinions on two more biosimilar products: trastuzumab and infliximab. Sixteen biosimilars remain under review at the agency.

EMA’s Pilot On Bespoke Scientific Advice For Biosimilars Attracts Monoclonal Antibody Makers

Monoclonal antibody developers are showing interest in the European Medicines Agency’s pilot project that is offering bespoke scientific advice on biosimilars.

EMA Addresses Need For Guideline On Antivirals & MAbs For COVID-19

New EU guidance will cover non-clinical and clinical development, trial design, endpoints, safety issues and comparators, as well as the use of immunobridging studies.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts